Goserelin Acetate
FDA-approved product (implant, implantation), marketed as Zoladex.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Breast cancer
- Breast carcinoma
- Carcinoma
- Neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Gonadotropin releasing hormone analogues
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA57.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli58.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis60.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Goserelin Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
NCT00186121 · start 2000-10
Registered record
- Registry ID
- NCT00186121
- Conditions
- Breast Cancer
- Interventions
- Anastrozole (Arimidex); Goserelin (Zoladex)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2000-10
- Completion
- 2013-06
- Enrolment
- 35
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventionAnastrozole (Arimidex); Goserelin (Zoladex)PhasePhase 2Registry statusCompletedRaloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer
NCT00031850 · start 2000-03
Registered record
- Registry ID
- NCT00031850
- Conditions
- Breast Cancer
- Interventions
- goserelin acetate; raloxifene
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2000-03
- Completion
- 2007-05
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventiongoserelin acetate; raloxifenePhaseNot applicableRegistry statusCompletedAbarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
NCT00841113 · start 1999-01
Registered record
- Registry ID
- NCT00841113
- Conditions
- Prostate Cancer
- Interventions
- Abarelix; Goserelin plus Bicalutamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1999-01
- Completion
- 2003-02
- Enrolment
- 177
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionAbarelix; Goserelin plus BicalutamidePhasePhase 3Registry statusCompletedRandomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients
NCT00309478 · start 1990-12
Registered record
- Registry ID
- NCT00309478
- Conditions
- Early-stage Breast Cancer
- Interventions
- Cyclophosphamide; Methotrexate; Fluorouracil implant; Goserelin; Tamoxifen
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1990-12
- Completion
- 2004-06
- Enrolment
- 1,099
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEarly-stage Breast CancerInterventionCyclophosphamide; Methotrexate; Fluorouracil implant; Goserelin +1 morePhasePhase 3Registry statusCompletedMK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
NCT01240928
Registered record
- Registry ID
- NCT01240928
- Conditions
- Metastatic Breast Cancer
- Interventions
- MSK-2206; Exemestane; Goserelin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Withdrawn
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic Breast CancerInterventionMSK-2206; Exemestane; GoserelinPhasePhase 1Registry statusWithdrawn